BioTuesdays

Author - Melane Sampson

CymaBay Therapeutics
Developments

CymaBay reports positive seladelpar data in PBC

CymaBay Therapeutics (NASDAQ:CBAY) presented new data from a second interim analysis of its ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC), a type of liver disease that damages...

April 11, 2018
Volition
Markets

VolitionRx closes $8.4-million stock offering

VolitionRx (NYSE American:VNRX) closed an offering of 3.5 million common shares at a price of $2.40 a share for gross proceeds of $8.4-million. Volition, which develops blood tests to help diagnose a range of cancers...

March 14, 2018
Can-Fite Logo
Markets

Maxim cuts Can-Fite Biopharma to hold; removes PT

Maxim Group downgraded Can-Fite Biopharma (NYSE American:CANF) to “hold” from “buy” and removed its previous $7 price target after the company announced a $5-million registered direct offering. The stock was quoted at...

March 9, 2018
Markets

Maxim lowers BioLineRx PT to $2 from $3

Maxim Group reduced its price target for BioLineRx (NASDAQ:BLRX) to $2 from $3 after the company reported fourth quarter results. The stock was quoted at $1 in afternoon trading on March 6. BioLineRx, which focuses on...

March 6, 2018
Evotec
Developments

Evotec, MaRS announce first LAB 150 project

Evotec AG (Frankfurt Stock Exchange:EVT) and MaRS Innovation announced the first project to be developed under their LAB150 partnership would target an unmet medical need in skin inflammatory conditions. The project...

February 15, 2018